Rathbones Group PLC Sells 48,235 Shares of Johnson & Johnson $JNJ

Rathbones Group PLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 5.4% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 850,658 shares of the company’s stock after selling 48,235 shares during the quarter. Rathbones Group PLC’s holdings in Johnson & Johnson were worth $129,938,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Brighton Jones LLC lifted its holdings in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares during the period. Wealth Group Ltd. acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth about $218,000. Smart Money Group LLC boosted its position in Johnson & Johnson by 6.5% in the first quarter. Smart Money Group LLC now owns 6,687 shares of the company’s stock valued at $1,109,000 after buying an additional 407 shares in the last quarter. Allworth Financial LP grew its stake in Johnson & Johnson by 1.8% during the first quarter. Allworth Financial LP now owns 329,321 shares of the company’s stock worth $51,022,000 after buying an additional 5,958 shares during the last quarter. Finally, Round Rock Advisors LLC increased its holdings in shares of Johnson & Johnson by 1.9% during the first quarter. Round Rock Advisors LLC now owns 9,681 shares of the company’s stock worth $1,605,000 after buying an additional 179 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.3%

Shares of JNJ opened at $186.50 on Friday. The stock’s fifty day simple moving average is $184.25 and its 200-day simple moving average is $168.70. The firm has a market capitalization of $449.34 billion, a PE ratio of 18.00, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.48. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion during the quarter. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is 50.19%.

Analyst Upgrades and Downgrades

A number of research firms recently commented on JNJ. Bank of America increased their price target on Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 15th. Loop Capital set a $190.00 target price on Johnson & Johnson in a report on Wednesday, October 22nd. Argus set a $210.00 target price on Johnson & Johnson in a research note on Wednesday, October 15th. Barclays upped their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Finally, Cowen restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $199.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.